ArticleJournal of the Canadian Association of Gastroenterology2022
Fecal Microbiota Transplantation for Severe or Fulminant
Article in Journal of the Canadian Association of Gastroenterology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07597421 (Fecal Microbiota Transplantation for the Treatment of Patients With Parkinson's Disease.), which is not on this map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Fecal Microbiota Transplantation for the Treatment of Patients With Parkinson's Disease.
Who cites it
18 citing papers in PubMed, 28 citations in OpenAlex.
- PediatricJPGN reports · 2026Article
- Ecological and dietary strategies to constrain Clostridioides difficile.Cell host & microbe · 2026Review
- Towards a Standard Protocol for Fecal Microbiota Transplantation in Irritable Bowel Syndrome.Journal of neurogastroenterology and motility · 2026Review
- Microbiota in pancreatic ductal adenocarcinoma progression and therapy: The hidden players.Chinese medical journal · 2026Review
- Management ofEClinicalMedicine · 2025Review
- Discordance in Clinical Indicators With Sequential Fecal Microbiota Transplantation: A Case of FulminantACG case reports journal · 2025Article
- Fecal microbiota transplantation: application scenarios, efficacy prediction, and factors impacting donor-recipient interplay.Frontiers in microbiology · 2025Review
- Fecal microbiota transplantation: current challenges and future landscapes.Clinical microbiology reviews · 2024Review
- Review
- Reviewing theMicroorganisms · 2024Review
- Microbiota-Based Live Biotherapeutic Products forInfection and drug resistance · 2024Review
- Review
- Article
- Effect of microbiome group on immune checkpoint inhibitors in treatment of gastrointestinal tumors.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- [Bacterial gut microbiota-key player in sepsis].Medizinische Klinik, Intensivmedizin und Notfallmedizin · 2023Review
- Microbial ecology betweenBioscience of microbiota, food and health · 2023Review
- The gut microbiome dysbiosis and regulation by fecal microbiota transplantation: umbrella review.Frontiers in microbiology · 2023Review
- Resolution rates in clinical trials for microbiota restoration for recurrentTherapeutic advances in gastroenterology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSevere or fulminant
aimThis systematic review determines the safety and efficacy of FMT in medically refractory SFCDI.
methodsA systematic search of the literature was conducted using PubMed (1965 to 2020), Web of Science (1900 to 20), EMBASE (1974 to 2020), and Cochrane Review (1945 to 2020). Quality appraisal by NIH Study Quality Assessment tools, and data extraction were performed by two teams of independent researchers. The primary outcome was resolution of SFCDI 4 weeks after the final FMT. Pooled resolution rates were calculated using generalized linear mixed models estimates.
resultsTwo hundred and forty patients from 10 studies (8 case series, 1 case-control and 1 randomized study) were included with 209 individual patient-level data. FMT resulted in resolution of SFCDI within 4 weeks in 211/240 individuals for a pooled estimate of 88% (95% confidence interval [CI]: 0.83 to 0.91). The mean number of FMT required was 1.6 for severe and 2.0 for fulminant CDI resolution. The pooled proportional estimates for patients requiring CDI-directed antimicrobials after FMT was 50% (95% CI: 0.06 to 0.94) for severe CDI and 67.0% (95% CI: 0.30 to 0.91) for fulminant CDI. Serious adverse event rates were low.
conclusionFMT appears effective in treating SFCDI patients with low adverse events, but requires multiple treatments with a significant proportion of patients requiring additional anti-CDI antibiotics to achieve resolution. The optimal route of FMT delivery remains unknown. The presence of pseudomembranous colitis may guide additional FMT or anti-CDI antibiotic treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.